Victory Capital Management Inc. Purchases 109,462 Shares of Elevance Health, Inc. $ELV

Victory Capital Management Inc. raised its position in shares of Elevance Health, Inc. (NYSE:ELV) by 31.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 461,693 shares of the company’s stock after acquiring an additional 109,462 shares during the period. Victory Capital Management Inc. owned approximately 0.21% of Elevance Health worth $149,182,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of ELV. Nilsine Partners LLC grew its stake in shares of Elevance Health by 1.5% in the 3rd quarter. Nilsine Partners LLC now owns 1,918 shares of the company’s stock worth $620,000 after buying an additional 29 shares in the last quarter. HBK Sorce Advisory LLC lifted its holdings in shares of Elevance Health by 4.4% in the 3rd quarter. HBK Sorce Advisory LLC now owns 743 shares of the company’s stock valued at $260,000 after acquiring an additional 31 shares during the last quarter. Detalus Advisors LLC grew its position in Elevance Health by 1.8% in the third quarter. Detalus Advisors LLC now owns 1,726 shares of the company’s stock worth $558,000 after acquiring an additional 31 shares in the last quarter. Forum Financial Management LP boosted its holdings in shares of Elevance Health by 1.1% in the 3rd quarter. Forum Financial Management LP now owns 2,971 shares of the company’s stock worth $960,000 after purchasing an additional 33 shares during the period. Finally, Activest Wealth Management lifted its position in Elevance Health by 66.7% in the third quarter. Activest Wealth Management now owns 85 shares of the company’s stock worth $27,000 after buying an additional 34 shares during the last quarter. Institutional investors own 89.24% of the company’s stock.

Elevance Health Stock Performance

ELV stock opened at $283.69 on Wednesday. Elevance Health, Inc. has a one year low of $273.71 and a one year high of $458.75. The firm has a market cap of $62.61 billion, a price-to-earnings ratio of 11.29, a PEG ratio of 1.63 and a beta of 0.51. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.54 and a current ratio of 1.54. The firm has a 50-day simple moving average of $348.03 and a two-hundred day simple moving average of $335.80.

Elevance Health (NYSE:ELV) last posted its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, topping the consensus estimate of $3.10 by $0.23. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The firm had revenue of $49.31 billion during the quarter, compared to analyst estimates of $49.52 billion. During the same quarter in the previous year, the business posted $3.84 EPS. Elevance Health’s revenue was up 9.6% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, equities analysts forecast that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be given a dividend of $1.72 per share. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $6.88 annualized dividend and a yield of 2.4%. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s dividend payout ratio is currently 27.23%.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Weiss Ratings lowered Elevance Health from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, February 2nd. Mizuho set a $413.00 target price on Elevance Health in a research note on Friday, January 9th. Jefferies Financial Group dropped their target price on shares of Elevance Health from $401.00 to $395.00 and set a “buy” rating on the stock in a research note on Friday, January 30th. Sanford C. Bernstein lowered their price target on Elevance Health from $431.00 to $409.00 and set an “outperform” rating for the company in a report on Friday, January 30th. Finally, Wolfe Research set a $425.00 price objective on Elevance Health and gave the stock an “outperform” rating in a report on Thursday, January 8th. Twelve investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $390.55.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.